Paper Details
- Home
- Paper Details
Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
Author: EgamiYasuyuki, KawamuraAkito, KawanamiShodai, MatsuhiroYutaka, Matsunaga-LeeYasuharu, NakamuraHitoshi, NishinoMasami, OkamotoNaotaka, SugaeHiroki, TanakaAkihiro, TanouchiJun, TsudaMasaki, UkitaKohei, YanoMasamichi, YasumotoKoji
Original Abstract of the Article :
The short-term effectiveness of tolvaptan (TLV) for heart failure (HF) has been established, but the long-term effects are controversial. We investigated HF patients who could not discontinue both loop diuretics and TLV at discharge from AURORA (Acute Heart Failure Registry in Osaka Rosai Hospital)....See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1536/ihj.21-396
データ提供：米国国立医学図書館（NLM）
Tolvaptan for Heart Failure: Finding the Right Dose for Long-Term Management
Heart failure (HF) is a serious condition that affects millions of people worldwide. Tolvaptan (TLV) has shown promise in treating HF, but optimal long-term dosage remains a subject of debate. This study investigates the effectiveness of long-term TLV therapy in reducing HF rehospitalizations, focusing on the impact of different TLV doses in diuretic-dependent HF patients.
Long-Term Tolvaptan Therapy: A Potential Solution for Reducing HF Rehospitalizations
The study reveals that the TLV dose is a critical factor influencing HF rehospitalizations. While TLV therapy can be beneficial in reducing hospital readmissions, the researchers found that long-term low-dose TLV (≤ 7.5 mg/day) was more effective than higher doses in achieving this goal. These findings provide valuable insights for physicians managing HF patients and underscore the importance of individualizing treatment plans to optimize patient outcomes.
Heart Failure Management: Balancing Benefits and Risks
The study underscores the need for careful consideration when using TLV therapy for HF. While the drug offers potential benefits in reducing hospital readmissions, the research suggests that finding the optimal dose is crucial. Patients should work closely with their physicians to determine the appropriate TLV dose based on their individual needs and risk factors. This study emphasizes the importance of continued research to refine HF management strategies and ensure the best possible outcomes for patients.
Dr. Camel's Conclusion
This study highlights the complex challenges of managing HF and finding the right balance between benefits and risks. Like a camel navigating a desert landscape, HF patients must be carefully guided through their treatment journey. This study underscores the importance of individualized treatment plans, taking into account patient-specific factors to optimize outcomes and improve quality of life.
Date :
- Date Completed 2022-02-04
- Date Revised 2022-02-04
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.